Daiva Urboniene

Prof. Dr. Daiva Urboniene

Department of Laboratory Medicine, Lithuanian University of Health Sciences, Kaunas, Kauno Miestas, Lithuania
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Immunotoxicology
Verified
Journal Article
Open access
AVAgne Vitkauskaite
Agne Vitkauskaite
DUDaiva Urboniene
Daiva Urboniene
JCJoana Celiesiute
Joana Celiesiute
Kristina JarieneKristina Jariene
Kristina Jariene
ESErika Skrodeniene
Erika Skrodeniene
DVDaiva Vaitkiene
Daiva Vaitkiene
There is increasing evidence that host inflammatory responses play an important role in the development and progression of cancers. There are some data that cancer is associated not only with inflammation at the site of the lesion, but also with dysregulations of the host overall systemic immune response. In the case of cervical cancer, inflammation is an important factor associated with the development, progression, and potential metastasis of the disease. What is unclear still in the potential for modifications of host responses to human papillomaviruses (HPV) – a known causative agent of CC, that could be induced by cigarette smoking. In particular, it remains to be determined how the inflammation induced by HPV infection could impact on CC incidence/severity. In this prospective study, serum levels of 10 cytokines were evaluated using Multiplex and ELISA assays. The samples were the sera of 43 CC patients and 60 healthy (NILM) controls. All outcomes were evaluated in relation to host HPV and to their smoking status. The results in indicated that serum sTREM-1, TNFα, IFNβ, IL-1β, and IL-6 levels were significantly increased in CC (HPV+) patients compared to healthy NILM controls. A similar trend was observed for IL-10 and IL-2 levels. Within the two groups, differences in cytokine levels between smokers and never smokers were not remarkable. The findings here support the hypothesized role of systemic inflammation in the pathophysiology of CC.

1 March 2013 in Respiratory Medicine
Verified
Journal Article
Closed access
DUDaiva Urboniene
Daiva Urboniene
ABAgne Babusyte
Agne Babusyte
JLJan Olof Lötvall
Jan Olof Lötvall
RSRaimundas Sakalauskas
Raimundas Sakalauskas
Brigita GradauskieneBrigita Gradauskiene
Brigita Gradauskiene

21 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DSDonatas Stakišaitis
Donatas Stakišaitis
LKLinas Kapočius
Linas Kapočius
Angelija ValančiūtėAngelija Valančiūtė
Angelija Valančiūtė
IBIngrida Balnyte
Ingrida Balnyte
TTTomas Tamošuitis
Tomas Tamošuitis
VLVaiva Lesauskaite
Vaiva Lesauskaite
Sex differences identified in the COVID-19 pandemic are necessary to study. It is essential to investigate the efficacy of the drugs in clinical trials for the treatment of COVID-19, and to analyse the sex-related beneficial and adverse effects. The histone deacetylase inhibitor valproic acid (VPA) is a potential drug that could be adapted to prevent the progression and complications of SARS-CoV-2 infection. VPA has a history of research in the treatment of various viral infections. This article reviews the preclinical data, showing that the pharmacological impact of VPA may apply to COVID-19 pathogenetic mechanisms. VPA inhibits SARS-CoV-2 virus entry, suppresses the pro-inflammatory immune cell and cytokine response to infection, and reduces inflammatory tissue and organ damage by mechanisms that may appear to be sex-related. The antithrombotic, antiplatelet, anti-inflammatory, immunomodulatory, glucose- and testosterone-lowering in blood serum effects of VPA suggest that the drug could be promising for therapy of COVID-19. Sex-related differences in the efficacy of VPA treatment may be significant in developing a personalised treatment strategy for COVID-19.

16 February 2017 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
LKLaura Kyguoliene
Laura Kyguoliene
ASAlbertas Skurvydas
Albertas Skurvydas
NENerijus Eimantas
Nerijus Eimantas
NBNeringa Baranauskienė
Neringa Baranauskienė
DMDalia Mickeviciene
Dalia Mickeviciene
MBMarius Brazaitis
Marius Brazaitis

4 August 2022 in Medicina
Verified
Journal Article
Open access
PDF file
RKRasa Karaliūtė
Rasa Karaliūtė
ALArnoldas Leleika
Arnoldas Leleika
IAIeva Apanavičiūtė
Ieva Apanavičiūtė
TKTomas Kazakevičius
Tomas Kazakevičius
VMVaida Mizarienė
Vaida Mizarienė
GŠGintarė Šakalytė
Gintarė Šakalytė
Background and objectives: To identify clinical, echocardiographic, and laboratory parameters that affect the early recurrence of atrial fibrillation (AF) after restoring sinus rhythm (SR) by electrical cardioversion (ECV), and to determine whether left atrial (LA) strain, as a noninvasive indicator reflecting fibrosis, is associated with laboratory indicators affecting the development of fibrosis, interleukin 6 (IL-6) or tumor necrosis factor α (TNF-α). Materials and Methods: The study included 92 persistent AF patients who underwent elective ECV. The effective maintenance of SR was evaluated after 40 ± 10 days of ECV. Echocardiography, inflammatory markers (high-sensitivity c-reactive protein (hs-CRP), IL-6, and TNF-α), and natriuretic peptides (N-terminal pro b-type natriuretic peptide (NT-proBNP) and N-terminal pro a-type natriuretic peptide (NT-proANP)) were assessed. Results: After a 40 ± 10 days observation period, 51 patients (55.4%) were in SR. Patients with AF recurrence had a significantly longer duration of AF (p = 0.008) and of arterial hypertension (p = 0.035), lower LA ejection fraction (p = 0.009), lower LA strain (p < 0.0001), higher left ventricular global longitudinal strain (p = 0.001), and a higher E/e‘ ratio (p < 0.0001). LA strain was an independent predictor of early AF recurrence (OR: 0.65; 95% Cl 0.5–0.9, p = 0.004). LA strain < 11.85% predicted AF recurrence with 70% sensitivity and 88% specificity (AUC 0.855, 95% CI 0.77–0.94, p < 0.0001). LA strain demonstrated the association with NT-proBNP (r = −0.489, p < 0.0001) and NT-proANP (r = −0.378, p = 0.002), as well as with hs-CRP (r = −0.243, p = 0.04). Conclusions: LA strain appeared to be the most accurate predictor of early AF recurrence after ECV in patients with persistent AF. LA strain inversely correlated with NT-proBNP and NT-proANP, but no significant association with any of the inflammatory markers was identified.

19 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ABArenida Bartkeviciene
Arenida Bartkeviciene
AJAldona Jasukaitiene
Aldona Jasukaitiene
IZInga Zievyte
Inga Zievyte
DSDarius Stukas
Darius Stukas
SISandra Ivanauskiene
Sandra Ivanauskiene
AGAntanas Gulbinas
Antanas Gulbinas
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), has an immune suppressive environment that allows tumour cells to evade the immune system. The aryl-hydrocarbon receptor (AHR) is a transcription factor that can be activated by certain exo/endo ligands, including kynurenine (KYN) and other tryptophan metabolites. Once activated, AHR regulates the expression of various genes involved in immune responses and inflammation. Previous studies have shown that AHR activation in PDAC can have both pro-tumorigenic and anti-tumorigenic effects, depending on the context. It can promote tumour growth and immune evasion by suppressing anti-tumour immune responses or induce anti-tumour effects by enhancing immune cell function. In this study involving 30 PDAC patients and 30 healthy individuals, peripheral blood samples were analysed. PDAC patients were categorized into Low (12 patients) and High/Medium (18 patients) AHR groups based on gene expression in peripheral blood mononuclear cells (PBMCs). The Low AHR group showed distinct immune characteristics, including increased levels of immune-suppressive proteins such as PDL1, as well as alterations in lymphocyte and monocyte subtypes. Functional assays demonstrated changes in phagocytosis, nitric oxide production, and the expression of cytokines IL-1, IL-6, and IL-10. These findings indicate that AHR’s expression level has a crucial role in immune dysregulation in PDAC and could be a potential target for early diagnostics and personalised therapeutics.